Oncology Journals review
Assessing the value of systemic Therapy and radiation therapy in Stage I Nodal Marginal Zone Lymphoma
Oncologyme
/ Mar 26, 2023

In a large Propensity score matched retrospective study was conducted to assess the value of systemic Therapy and radiation therapy...
CheckMate 914 trial: adjuvant Immunotherapy in Renal Cell Carcinoma
Oncologyme
/ Apr 30, 2023

In the phase 3 CheckMate 914 trial, Adjuvant #nivolumab plus #ipilimumab failed to improve the clinical outcomes in patients with...
Colonoscopy benefits in CRC screening
Oncologyme
/ Mar 26, 2023

Although #colonoscopy is widely used as a #screening test to detect colorectal cancer (#CRC), it is more invasive and resources...
DESTINY-Breast02 trial: Trastuzumab deruxtecan after failure on TDM-1, An Update
Oncologyme
/ Apr 30, 2023

In the phase 3 DESTINY-Breast02 trial, #Trastuzumab deruxtecan (T-DXd) improved the PFS and OS in patients with HER2-positive metastatic breast...
Dexamethasone for dysnea treatment
Oncologyme
/ Feb 15, 2023

Patients with cancer often suffer shortness of breath for different reasons. Many physicians prescribe empirical dexamethasone as a symptomatic treatment....
ECHELON-1 trial
Oncologyme
/ Feb 15, 2023

The addition of #brentuximab_vedotin shows survival benefits in patients with previously untreated stage III or IV classic #Hodgkin’s_lymphoma. The ECHELON-1...
GeparOLA trial: Investigating the effectiveness of neoadjuvant Olaparib and Paclitaxel in treating early HER2-negative breast cancer with high homologous recombination deficiency (HRD).
May 07, 2023

In the phase II GeparOLA trial, Neoadjuvant #Olaparib plus paclitaxel was not superior to Paclitaxel-carboplatin regarding long-term outcomes in patients...
In a phase III Indian study, the addition of weekly carboplatin significantly improved overall survival and event-free survival when added to a taxane-anthracycline neoadjuvant chemotherapy regimen for patients with locally advanced triple-negative breast cancer.
Oncologyme
/ Apr 30, 2023
In the phase 2, PACE trial, the combination of #palbociclib plus fulvestrant did not improve significantly PFS compared with fulvestrant...
KEYNOTE 355 trial
Oncologyme
/ Feb 15, 2023

Adding #pembrolizumab to chemotherapy resulted in significantly longer overall survival among patients with previously untreated advanced #triple_negative_breast_cancer whose tumors expressed...
PURE 01 trial: Neoadjuvant Pembrolizumab for Muscle-invasive Bladder Carcinoma
Oncologyme
/ Apr 30, 2023

In the phase II PURE-01 trial, #neoadjuvant #pembrolizumab has shown to improve the clinical outcomes in patients with muscle-invasive #bladder...
Latest Articles
- 1
- 2